We serve Chemical Name:1-(3-Methylquinoxalin-2-yl)ethanone CAS:22059-64-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:1-(3-Methylquinoxalin-2-yl)ethanone
CAS.NO:22059-64-9
Synonyms:2-acetyl-3-methyl-quinoxaline;2-methyl-3-acetylquinoxaline;3-methyl-2-acetyl-quinoxaline;2-Acetyl-3-methylchinoxalin;MFCD09864318
Molecular Formula:C11H10N2O
Molecular Weight:186.21000
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:292.512ºC at 760 mmHg
Density:1.18g/cm3
Index of Refraction:1.616
PSA:42.85000
Exact Mass:186.07900
LogP:2.14080
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 2-acetyl-3-methyl-quinoxaline chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD09864318 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-Acetyl-3-methylchinoxalin Use and application,2-acetyl-3-methyl-quinoxaline technical grade,usp/ep/jp grade.
Related News: The program will run alongside our ongoing Phase 3 INSPIRE Trial, and is expected to continue until commercial launch in such countries. 1-(3-Methylquinoxalin-2-yl)ethanone manufacturer The bulk-buy program, which currently covers 25 types of medicines, allows no more than three successful bidders access to China��s public hospitals, where most Chinese people buy their drugs. 1-(3-Methylquinoxalin-2-yl)ethanone supplier He pointed out that Taiwan had 10 confirmed cases, versus more than 14,000 in mainland China. 1-(3-Methylquinoxalin-2-yl)ethanone vendor Pre-approval Access Programs (also known as expanded access, early access, compassionate use, named patient supply) are regulatory-compliant processes permitting experimental agents in development to be made available upon the request of a physician or a patient for appropriate patients for whom no alternative treatment option exists in their country. 1-(3-Methylquinoxalin-2-yl)ethanone factory Higher-risk MDS is a disease with significant unmet need, and we are pleased to be able to support healthcare professionals seeking access to rigosertib, ahead of its commercial launch,�� said Mark Corbett, EVP, Inceptua Medicines Access.
